Mayu Takagi
1602-111 St. Clair Ave W
Toronto, ONM4V 1N5

Deep Lens
About Simon Arkell• He is the co-founder of 7 companies including Deep Lens and Predixion
Personal Life
• Born July 1, 1966 (52 years old)
• Came to the US in 19786 from Australia on a pole vaulting （棒高跳び）scholarship• Represented Australia in the World Championship, World Cups, and Olympic Games
from 1986-1996• Holds the world record for left handed pole vaulters since 1995
• In 1996, he retired from this world
Education• Bachelor of Arts in Economics – University of Adelaide (only there for 1 year until hewent to the US for a sports scholarship)• Bachelor of Arts in Economics – The University of New Mexico (1986-1991)• MBA – Cal Poly (SLO) (1992-1994)
Experience• 2018-Now President and Co-Fdounder of Deep Lens
o An AI company focused on accelerating the use of digital pathology to help
match cancer patients to life saving available clinical trials
o Currently based by investors and VCs such as Sierra Ventures, Rev1 Ventures,
and Tamarind Hill Fundo Has an exclusive license to a cutting edge digital pathology platform from thelargest pediatric oncology research institution in the USo Deep Lens is adding AI-powered image detection and workflow support,
telepathology, cloud storage, and built-in APIs for integration by hardware
and software vendors and biopharma companieso This platform is being used by hundreds of pathologists from more than 65
major institutions in 8 countries• 2017-2018 (8mos) Consultant/Interim Chief Strategy Officer at ClearStory Datao A big data analytics company with an end-to-end, cloud based , in-memoru
solution that uses machine learning to automatically blend data and provideinsights to large enterprise customers globallyo Based by some of the best venture funds such as Kleiner Perkins Caufield
Byers, Adnreesse Horowitz, Google Ventures etc.
• 2016-20177 (11mos) General Manager of Software Platforms and Analytics at
Greenwave Systems Inc.

Mayu Takagi
1602-111 St. Clair Ave W
Toronto, ONM4V 1N5•

•

•
•
•
•

2009-2016 (7 years) Founder and CEO of Predixion Software Inc
o Predixion Software – a venture backed predictive analytics company thatraised over $40M from major VCs and investors before it was acquired by
Greenwave Systems in 20162009-2010 (10 mos) Operating Partner at Triton Pacfiic Capital Partnerso Focused on growth equity investments and buyouts of mid sized UScompanies
o Also served as an advisor to Triton’s portfolio companies (Custom Credit
Systems and DB Technology) on strategic market entry and partnership
opportunities
2002-2005 (3 years 4 mos) Principal at Gramercy Venture Advisorso Ran the Orange County Office and worked with US and Australian techcompanies with VC fund raising, trade sale, and US market entry work
1998-2001 (3 years)Co-founded Versifi as a spin out from GDI and served as VPBusiness Developmento Sold company to Reef (Belgium) in 2000 for US$48M
1997-1998 (1 year)VP Internet Services at GDI
1995-1996 (1 year 8mos) Co-founder and General Manager of Telephone NetworkConnections (an Australian switchless reseller and consultancy)o Sold company to LCR Telecom (UK) in 1996

Committees/Organizations• He currently serves on the President’s Council of Advisors and the Dean’s Advisory
Council for the Orfalea School of Business at Cal Poly, San Luis Obispo since May
2015
o Mentors startups at the Cal Poly Center for Innovation and Entrepreneurship(CIE)• Member of the Digital Pathology Association since July 2018
Honors and Awards• CEO of the Year- Mid Sized Companies (Oct 2015)
Publications• Co-wrote an article with Jeff Elton, MD for Lifesciences and Predictive Health atAccenture https://hbr.org/2014/10/create-a-strategy-that-anticipates-and-learns
o The article talks about how although there is a lot of talk around using
predictive tools to analyze big data but people are missing out on an evenbigger opportunity: managers can use digital technology to acquire andassess the information for real-time strategic decision makingo It is increasingly important for business leaders to predict and influence whatwill come nexto Data analysis can help us crunch key factors and connect insight and strategy
faster than everMayu Takagi
1602-111 St. Clair Ave W
Toronto, ON
M4V 1N5o Machin learning tools can be used to reveal meaningful patterns andhighlight gaps in markets → this can identify opportunities for new business
partnershipso It will become more important for business leaders to invest in enabling data
infrastructure and advance analytics, embedd predictive approaches
throughout the organization, move the company’s focus to planning andcoordination that is analytics-driveno Some companies are beginning to do this like Amazon – analyzes pools ofdata to predict who their customers are and what they will buy next to drive
strategic plans for new devices and service offerings

Volunteer Work• He is the Co-founder and MC of the “Megan’s Wings Gala” that raises money forfamilies of children diagnosed with cancer• Since Dec 2018 he has been volunteering at the J.F. Shea Therapeutic Riding Centerand encourages people to donate to the causeo This is a center that kids therapy through horse back riding
Conferences• Will be attending a conference on April 23, 2019 in Cambridge, MA that focuses on
discussing uses of AI for clinical trial recruitment and translational researchhttps://www.linkedin.com/pulse/ai-machine-learning-clinical-trials-fda-formallyweighs-lavender/• Simons will be presenting The Cal Poly Center for Innovation and Entrepreneurship’s
annual Spring Entrepreneurship Forum on May 14, 2019o He will be discussing the ever-increasing role of AI in the startup world• The Deep Lens executive team was at JPMorgan Chase & Co.’s 37th annual Healthcare
Conference in San Francisco from Jan 7-9, 2019

Connections• Margaretta Colangelo – Managing Partner at Deep Knowledge Ventures personallycongratulated Simon on LinkedIN when he posted the news about their Series A funding
https://www.linkedin.com/in/margarettacolangelo/• Simon often likes posts by Jeff Elton – Chief Executive Officer at Concerto Health AI
https://www.linkedin.com/in/jelton/detail/background-image/• Tom Walker – CEO of Rev1 Ventures wrote an article congratulating Deep Lens for theirsuccess https://www.linkedin.com/pulse/rev1-portfolio-company-deep-lens-seesimpressive-growth-tom-walker/

Mayu Takagi
1602-111 St. Clair Ave W
Toronto, ONM4V 1N5
Twitter Activity• On Dec 2 2018, Simon tweeted that Deep Lens made the list of top healthcare AIcompanies• Shared this as a great article https://www.cio.com/article/3305951/the-promise-ofartificial-intelligence-in-diagnosing-illness.html - an article that he and his co-founder arefeatured ino The article talks about the capability that AI has in precisely diagnosing illnesseso This realization has led Med schools are now offering courses in technology
infrastructure, deep learning, and data management alongside biology classeso AI can identify a cancer, feed new models, and help researchers quickly qualify
clinical trial participants• In Sep 2018 tweeted that Deep Lens is hardware and software players in the digitalpathology spaceo Says that edge computing is vital for local processing of image intensive AI deeplearning models
o Linked this: https://blogs.nvidia.com/blog/2018/09/12/nvidia-claraplatform/?ncid=so-ele-nrcmtghrtglsx3-58501▪ NVIDIA Clara platform – a combination of hardware and software thatbrings AI to the next generation of medical instruments as a powerful toolfor early detection, diagnosis, and treatment of diseases• Tweeted how digital pathology is not a thing in India because sanners cost too much andinstead, pathologists take photos with their iPhone down the eye piece of a microscopeand share it on Facebook to crowdsource opinions on cancer• Most of his activity on twitter is about digital pathology, deep learning, AI, and polevaulting• Congratulated ClearStory Data (http://www.clearstorydata.com) on their Series C funding
announcement• Often shares and retweets about ClearStory on twitte
About Deep Lens
• The company uses a platform called VIPER (Virtual Imaging for Pathology Educationand Research) which combines deep learning technology with pathology workflows tofacilitate patient identification for clinical trials• Software aims to help peer-to-peer collaboration and clinical research pathologists flagpatients who are eligible for a clinical trial at the time of diagnosis → fast-track trial• Their aim is to provide users with fast and accurate information + expert consultation forbetter patient care and advanced clinical research• By digitizing and modernizing pathology through whole slide imaging and AI, DeepLens is accelerating the identification of complex disease sub-types in real time
• Deep Lens VIPER uses deep learning methods to help identify and match patients toavailable clinical trials sooner than any other method• VIPER was originally developed for research purposes in one of the largest pediatriconcology facilities (Nationwide Children’s Hospital) in Columbus, Ohio

Mayu Takagi
1602-111 St. Clair Ave WToronto, ONM4V 1N5•••••o VIPER was built by expert pathology groups around the world that focused onspecific tumor types and subtypeso Nationwide Children’s Hospital facilitated the research projecto It was used as the platform for global oncology studies including the Cancer
Genome Atlas Projecto It was then commercialized by Deep Leno Leads to the right patient at the right time
Benefits of VIPER = speed, accuracy, collaboration, earlier detection, and matching
patients with clinical trials
o Speed – If you send in slides overnight or uploading images to VIPER, you willfind your images in your free version of VIPER ready for useo Accuracy – VIPER will provide insight by matching the case with other similarcancers → leads to predictive, precision, personalized medicineo Collaboration – VIPER has email capabilities for immediate collaboration withcolleagues▪ Can ask others for second opinions or crowd source opinions▪ They are also working to add a feature where you can quickly find experts
who can read your caseo Earlier Detection – improved accuracy with AI collaboration with otherpathologists around the world for second opinions leads to earlier detection andtreatmento Matching patients with Clinical Trials – one of the big challenges still withgetting a drug to market = complexity of the multiple phases of clinical trials▪ Patients and oncologists are frustrated by the complexity of identifying theright trials for the patients and getting the patient to access the trial as soon
as possible▪ Soon VIPER users will be able to match cases to available trials and checkfor patient eligibility to speed up access for the patient
Deep Lens charges institutions and companies a subscription fee but its free forindividual pathologists and pathology groups
Competitors: PathAI, Inspirata, and Proscia
But unlike competitors, Deep Learning is targeting hospitals, clinics, AND
pharmaceutical companies
Deep Lens has a Webinar that people can sign up for:https://register.gotowebinar.com/register/4556798791218777089?utm_campaign=Webinar:%20AI%20and%20the%20future%20of%20integrated%20Digital%20Pathology%20
workflows&utm_content=76886570&utm_medium=social&utm_source=linkedino Talks about AI and the future of digital pathology workflows

April 9 2019 – Deep Lens raises $14M for Ai-powered clinical trial recruitment
https://www.itnonline.com/content/deep-lens-closes-series-financing-digital-ai-pathologyplatform?utm_content=89120660&utm_medium=social&utm_source=linkedin&hss_channel=lis-kuA0_KRHNv

Mayu Takagi
1602-111 St. Clair Ave W
Toronto, ON
M4V 1N5•••••

The company receives $14M in Series A funding to expand its AI platform (Viper) for
recruiting clinical trial participants
Money will be used to further expand the company’s AI and platform productdevelopment activities
Financing was led by Northpond Ventureso Other investors: Revl Ventures, Sierra Ventures, and Tamarind-Hill Partners
This round comes only 3 months after Deep Lens closed its VC-led seed equity roundTotal funding to date = $17.5M

March 7, 2019 – Worldwide Clinical Trials and Deep Lens Enter Strategic Alliance toAccelerate Recruitment and Development Timelines for Oncology Trials• Worldwide Clinical Trials Inc. = an award-winning, full-service, midsize, global CRO• The two companies will pair Worldwide’s expertise in clinical cancer research and global
clinical trial operations with the Deep Lens VIPER platformo This will support a platform for sponsors, researchers, and care teams toaccelerate cancer diagnoses
October 12, 2018 – Deep Lens raises $3.2 million for AI cloud pathology platform
https://venturebeat.com/2018/10/12/deep-lens-raises-3-2-million-for-ai-cloud-pathologyplatform/• Dave Billiter is an graduate of Ohio Northern University and Columbus Southern
Univeristy who joined Nationwide Children’s Hospital in 2004, where he led the healthsystem’s informatics efforts → he oversaw the creation of what is now known as VIPER• Billiter teamed up with Simon Arkell to launch Deep Lens
• In October 2018, the company received $3.2M seed funding round led by Sierra
Ventures, Rev1 Ventures, and Tamarind-Hill Fund.